Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
Viridian Therapeutics Inc (NASDAQ: VRDN) closed the day trading at $14.90 down -1.59% from the previous closing price of $15.14. In other words, the price has decreased by -$1.59 from its previous closing price. On the day, 1.01 million shares were traded. VRDN stock price reached its highest trading level at $15.51 during the session, while it also had its lowest trading level at $14.41.
Ratios:
For a better understanding of VRDN, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 18.26 and its Current Ratio is at 18.26. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.04.
On June 14, 2023, BTIG Research started tracking the stock assigning a Buy rating and target price of $46.
On May 30, 2023, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $44.RBC Capital Mkts initiated its Outperform rating on May 30, 2023, with a $44 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 22 ’24 when Fairmount Funds Management LLC bought 476,190 shares for $21.00 per share. The transaction valued at 9,999,990 led to the insider holds 1,839,954 shares of the business.
Meisner Lara sold 27 shares of VRDN for $765 on Jun 16 ’23. The Chief Legal Officer now owns 29,971 shares after completing the transaction at $28.35 per share. On Jun 15 ’23, another insider, Meisner Lara, who serves as the Chief Legal Officer of the company, sold 2,269 shares for $28.02 each. As a result, the insider received 63,577 and left with 29,971 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VRDN now has a Market Capitalization of 950955200 and an Enterprise Value of 701484032. For the stock, the TTM Price-to-Sale (P/S) ratio is 3279.03 while its Price-to-Book (P/B) ratio in mrq is 3.42. Its current Enterprise Value per Revenue stands at 2234.026 whereas that against EBITDA is -2.763.
Stock Price History:
The Beta on a monthly basis for VRDN is 1.11, which has changed by -0.40323216 over the last 52 weeks, in comparison to a change of 0.2537824 over the same period for the S&P500. Over the past 52 weeks, VRDN has reached a high of $28.35, while it has fallen to a 52-week low of $10.93. The 50-Day Moving Average of the stock is -10.28%, while the 200-Day Moving Average is calculated to be -14.26%.
Shares Statistics:
Over the past 3-months, VRDN traded about 898.03K shares per day on average, while over the past 10 days, VRDN traded about 808380 shares per day. A total of 63.82M shares are outstanding, with a floating share count of 56.79M. Insiders hold about 11.02% of the company’s shares, while institutions hold 89.17% stake in the company. Shares short for VRDN as of 1713139200 were 9726768 with a Short Ratio of 10.83, compared to 1710460800 on 7619785. Therefore, it implies a Short% of Shares Outstanding of 9726768 and a Short% of Float of 17.899999.
Earnings Estimates
As of right now, 12.0 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$1.1 for the current quarter, with a high estimate of -$0.81 and a low estimate of -$1.36, while EPS last year was -$1.61. The consensus estimate for the next quarter is -$1.11, with high estimates of -$0.84 and low estimates of -$1.34.
Analysts are recommending an EPS of between -$3.44 and -$5.72 for the fiscal current year, implying an average EPS of -$4.54. EPS for the following year is -$4.57, with 12.0 analysts recommending between -$3.23 and -$6.69.
